Bomedemstat

also known as IMG-7289 · Bomedemstat ditosylate · BOMEDEMSTAT TOSYLATE · IMG-241 bis-tosylate salt · IMG-7289 DITOSYLATE · MK-3543

Small molecule targets KDM1A via inhibition

Developed for: essential thrombocythemia · acquired polycythemia vera · myelofibrosis · primary myelofibrosis · acute myeloid leukemia · myelodysplastic syndrome · small cell lung carcinoma
Investigated by: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) · Merck Sharp & Dohme LLC · Terrence J Bradley, MD · National Cancer Institute (NCI) · The University of Hong Kong · The University of Texas Health Science Center at San Antonio
+3 more
· United Lincolnshire Hospitals NHS Trust · University of Lincoln · University of Washington

Trials 17

today NCT07424950 · Ph 2 NCT07722611 · Ph 2/3 NCT07049939 · Ph 1 NCT06596668 · Ph 1 NCT06456346 · Ph 3 NCT06351631 · Ph 3 NCT06079879 · Ph 3 NCT05558696 · Ph 2 NCT05569538 · Ph 2 NCT05597306 · Ph 1 NCT05191797 · Ph 1/2 NCT05223920 · Ph 2 NCT04262141 · Ph 2 NCT04254978 · Ph 2 NCT04081220 · Ph 2 NCT03136185 · Ph 1/2 NCT02842827 · Ph 1/2

2017201820192020202120222023202420252026202720282029203020312032203320342035

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT07049939	Aug 2025 → Feb 2026	liver disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT06596668	Oct 2024 → Feb 2025	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT05597306	Nov 2022 → Nov 2026 expected	acute myeloid leukemia	Terrence J Bradley, MD	Recruiting	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT05191797	Apr 2022 → Aug 2023	small cell lung carcinoma	University of Washington	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT03136185	Jul 2017 → Mar 2022	myelofibrosis, primary myelofibrosis	Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)	Completed	No outcome recorded
Phase 1/2	NCT02842827	Oct 2016 → Oct 2018	acute myeloid leukemia, myelodysplastic syndrome	Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)	Completed	No outcome recorded
Phase 27 trials · 1 met primary
Phase 2	NCT07424950	Nov 2026 → Nov 2028 expected	myelofibrosis	United Lincolnshire Hospitals NHS Trust	Not yet recruiting	No outcome recorded
Phase 2	NCT05558696	Sep 2023 → Mar 2025	acquired polycythemia vera	Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)	Completed	No outcome recorded
Phase 2	NCT05569538	Dec 2022 → Dec 2024	myelofibrosis	The University of Hong Kong	Unknown	No outcome recorded
Phase 2	NCT05223920	Dec 2021 → Aug 2024	essential thrombocythemia, primary myelofibrosis	Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)	Completed	No outcome recorded
Phase 2	NCT04262141	Oct 2020 → Oct 2026 expected	acquired polycythemia vera, essential thrombocythemia	Terrence J Bradley, MD	Active not recruiting	No outcome recorded
Phase 2	NCT04254978	Sep 2020 → Mar 2023	essential thrombocythemia	Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)	Completed	Met primary
Phase 2	NCT04081220	Apr 2020 → Dec 2023 overdue	essential thrombocythemia	The University of Texas Health Science Center at San Antonio	Active not recruiting	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT07722611	Oct 2026 → Jun 2032 expected	acquired polycythemia vera	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded
Phase 33 trials
Phase 3	NCT06456346	Jul 2024 → Sep 2027 expected	essential thrombocythemia	Merck Sharp & Dohme LLC	Active not recruiting	No outcome recorded
Phase 3	NCT06351631	May 2024 → Dec 2034 expected	acquired polycythemia vera, essential thrombocythemia, myelofibrosis, primary myelofibrosis	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded
Phase 3	NCT06079879	Dec 2023 → Jul 2027 expected	essential thrombocythemia	Merck Sharp & Dohme LLC	Active not recruiting	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2024-08-27	Merck Sharp & Dohme LLC	Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia merck.com ↗

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

Field	Value	Cited text
Known as	Bomedemstat	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05597306 ↗ 14 NCT05569538 ↗ NCT06596668 ↗ NCT02842827 ↗ NCT07722611 ↗ NCT05191797 ↗ NCT05223920 ↗ NCT04254978 ↗ NCT05558696 ↗ NCT06079879 ↗ NCT06456346 ↗ Show 4 more sources
Known as	Bomedemstat ditosylate	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289 ↗
Known as	BOMEDEMSTAT TOSYLATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289 ↗
Known as	IMG-241 bis-tosylate salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289 ↗
Known as	IMG-7289	“This is an open-label, Phase 2 study of bomedemstat (IMG-7289), an inhibitor of lysine-specific demethylase 1 (LSD1), in combination with JAK inhibition (JAKi) in patients with...” NCT05569538 ↗ 4 “An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms” NCT05223920 ↗ “Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis” NCT07424950 ↗ NCT04081220 ↗ NCT04262141 ↗
Known as	IMG-7289 DITOSYLATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289 ↗
Known as	MK-3543	“An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms” NCT05223920 ↗
Action	Inhibit	“Lysine-specific histone demethylase 1 inhibitor” CHEMBL4297289 ↗ 1 “lysine-specific demethylase 1 (LSD1) inhibitor” NCT02842827 ↗
Modality	Small molecule	— CHEMBL4297289 ↗
Route	Oral	“oral administration” NCT02842827 ↗
Target	KDM1A	“Lysine-specific histone demethylase 1 inhibitor” CHEMBL4297289 ↗